

## Cardiac Resynchronization Therapy in Heart Failure: Rationale, Results, Indications, Limits and Perspectives

Andrea Mazza, Sergio Valsecchi, Umberto Riva, Maria Grazia Bendini, Massimo Leggio

Andrea Mazza, Maria Grazia Bendini, Cardiology Division, Santa Maria della Stella Hospital, Orvieto, Italy

Sergio Valsecchi, Umberto Riva, Boston Scientific Italy, Milan, Italy

Massimo Leggio, Department of Cardiovascular, Cardiac Rehabilitation Operative Unit, San Filippo Neri Hospital, Salus Infirmorum Clinic, Rome, Italy

Correspondence to: Massimo Leggio, MD, Department of Cardiovascular, Cardiac Rehabilitation Operative Unit, San Filippo Neri Hospital, Salus Infirmorum Clinic, Via della Lucchina 41, 00135 Rome, Italy.

Email: [mleggio@libero.it](mailto:mleggio@libero.it)

Telephone: +3906302511

Fax: +390630811972

Received: May 11, 2014

Revised: June 5, 2014

Accepted: June 10, 2014

Published online: July 10, 2014

through multi-parameter evaluations and to ensure correct device programming with periodic updates which are widely recommended but not so often performed. Whether indications should be extended will need to be evaluated in view of the known complications mainly associated with lead implantation.

© 2014 ACT. All rights reserved.

**Key words:** Cardiac resynchronization therapy; Heart failure

Mazza A, Valsecchi S, Riva U, Bendini MG, Leggio M. Cardiac Resynchronization Therapy in Heart Failure: Rationale, Results, Indications, Limits and Perspectives. *Journal of Cardiology and Therapy* 2014; 1(6): 121-126 Available from: URL: <http://www.ghrnet.org/index.php/jct/article/view/766>

### ABSTRACT

Heart Failure is the result of heterogeneous structural heart diseases, especially ischemic disease, and is becoming increasingly common in all Western countries. Many patients continue to be symptomatic in spite of progress in pharmacological therapy, and the risk of mortality remains high in the most advanced functional classes. Cardiac resynchronization therapy can be used as a therapeutic strategy for alleviating symptoms and reducing mortality in a considerable percentage of patients with heart failure. Cardiac resynchronization therapy provides both immediate and medium/long-term results. The immediate results are the reduced QRS duration, the synchrony restoration between the ventricles and between the lateral and septal walls of the left ventricle, the reduced mitral regurgitation and the increased stroke volume. In the medium/long term, left ventricular reverse remodeling occurs and left ventricular ejection fraction is increased. Several trials have documented both increased functional capacity and improvements in quality of life and New York Heart Association class. Moreover, cardiac resynchronization therapy has been seen to reduce HF hospitalizations and mortality and the total number of days of hospitalization. In order to reduce the percentage of non-responders to cardiac resynchronization therapy, it is necessary to optimize the prognostic stratification of candidates for implantation

### INTRODUCTION

Heart Failure (HF) is the result of heterogeneous structural heart diseases, especially ischemic disease, and is becoming increasingly common in all Western countries. Indeed, over than 7 million individuals in Europe<sup>[1]</sup> and over than 4 million in the United States<sup>[2]</sup> are currently affected. Moreover, this prevalence is expected to double over the next 20 years<sup>[3]</sup>, thus making HF the new cardiovascular epidemic<sup>[4]</sup>.

Since 1986, numerous clinical trials focused on HF therapy have been conducted, ranging from the simple control of risk factors to the implementation of advanced treatment modalities for patients with HF refractory to conventional therapy<sup>[5]</sup>.

However, many patients continue to be symptomatic in spite of progress in pharmacological therapy, and the risk of mortality remains high in the most advanced functional classes<sup>[6]</sup>. Cardiac resynchronization therapy (CRT) can be used as a therapeutic strategy for alleviating symptoms and reducing mortality in a considerable percentage of HF patients.

### RATIONALE

It is well known that QRS duration is inversely correlated with survival in HF patients in functional classes II-IV, and patients with QRS  $\geq 200$  ms have a 5-fold higher risk of death than those with

a narrow QRS<sup>[7]</sup>. In particular, left bundle branch block (LBBB) usually delays activation of the posterior/lateral wall of the left ventricle, leading to asynchronous contraction between the septum and posterior-lateral wall and reducing the left ventricular ejection fraction (LVEF).

CRT can correct this asynchronous contraction through the pre-excitation of the posterior-lateral wall of the left ventricle, thereby improving systolic function<sup>[8,9]</sup>. Indeed, the dyssynchrony due to prolonged QRS duration involves the heterogeneous propagation of electrical activity in the ventricle, which determines various degrees of impaired coordination in filling and contraction<sup>[10]</sup>. Consequently the contractile efficiency of the heart is compromised and the myocardial oxygen consumption increases, worsening the clinical course of HF.

It is therefore important to consider that 1/3 of HF patients have a QRS duration  $>120$  ms<sup>[11]</sup>, and that the incidence of LBBB is 10.9% in the first year of follow-up<sup>[12]</sup>. In these patients, CRT enables synchronous stimulation of both ventricles, which reduces QRS duration and improves left ventricular systolic performance, although modestly increasing the myocardial oxygen consumption<sup>[13]</sup>. The beneficial effects of CRT on left ventricular systolic function and on neurohormonal activation lead to clinical improvements in symptoms, exercise capability and quality of life, and reduce HF hospitalizations and mortality<sup>[14]</sup>.

## RESULTS

CRT provides both immediate and medium/long-term results. The immediate results are the reduced QRS duration, the synchrony restoration between the ventricles and between the lateral and septal walls of the left ventricle, the reduced mitral regurgitation and the increased stroke volume. In the medium/long term, left ventricular reverse remodeling occurs, left ventricular end-systolic volume (LVEsV) is reduced by at least 15% and LVEF is increased by a minimum of 5%.

On the clinical side, several trials have documented both increased functional capacity, as evaluated by means of the 6-minute walking test and the VO<sub>2</sub> peak, and improvements in quality of life and New York Heart Association (NYHA) class<sup>[15-23]</sup>. Moreover, CRT has been seen to reduce HF hospitalizations and mortality by 36%<sup>[22]</sup>, and the total number of days of hospitalization by 77%<sup>[17]</sup>. The COMPANION study<sup>[22]</sup> evaluated the efficacy of CRT, with or without an Implantable Cardioverter Defibrillator (ICD), versus medical therapy alone, in reducing the risk of death and hospitalizations in HF patients. In 1,520 patients with advanced HF (LVEF  $\leq 35\%$ , left ventricular end-diastolic diameter (LVEdD)  $\geq 60$  mm, NYHA class III-IV) and intraventricular conduction delay (QRS  $\geq 120$  ms), both CRT with and without ICD reduced the primary end-point of mortality/hospitalization for HF by 20% in one year compared with optimal medical therapy. It was clearly demonstrated that CRT in addition to optimal medical therapy with beta-blockers<sup>[24,25]</sup>, ACE-inhibitors<sup>[26,27]</sup> and mineralocorticoid antagonists<sup>[28]</sup>, further reduced mortality in HF patients, and that this reduction reached a value of 36% in the long term<sup>[22]</sup>.

The CARE-HF study<sup>[23]</sup> evaluated the effect of CRT on morbidity and mortality in 813 patients with advanced HF and a clinical and instrumental profile similar to that of the COMPANION study population. The primary end-point was the combination of all-cause death and hospitalization for major cardiovascular events over a mean follow-up of 29.4 months. In this study, CRT reduced the primary end-point by 37% compared with medical therapy (HR 0.63, 95% CI 0.51-0.77,  $P < 0.0001$ ) in subgroups that showed no statistically

significant differences.

These exciting results led to further studies in which the benefits of CRT have been assessed in patients in lower functional classes. Specifically, in the REVERSE study<sup>[29]</sup> the long-term benefits of CRT were evaluated in 610 European patients in NYHA class II (83%) or I (previously symptomatic), with QRS  $\geq 120$  ms, LVEF  $\leq 40\%$ , LVEdD  $\geq 55$  mm, with or without indication for an ICD, and undergoing optimized medical therapy. Patients were randomized 2:1 to CRT-ON or CRT-OFF and followed up prospectively for 24 months. The end-points of the study were the combined clinical score of all-cause mortality, hospitalizations for HF, cross-over due to worsening HF and NYHA class, and LVEsV reduction. Echocardiography revealed a significant improvement in LVEsV, left ventricular end-diastolic volume (LVEdV) and LVEF (69.7 vs 94.5 mL/m<sup>2</sup>, 103 vs 132 mL/m<sup>2</sup>, 34.8% vs 29.9%, CRT-ON vs CRT-OFF, respectively). Clinically, a significant 62% reduction was reported in mortality and hospitalizations for HF at 24 months (11.7% vs 24%, HR 0.38, 95% CI 0.20-0.73,  $P = 0.003$ , CRT-ON vs CRT-OFF).

Similarly, the MADIT-CRT study<sup>[30]</sup> enrolled 1,820 patients in NYHA class I or II (85%) and with QRS  $\geq 130$  ms and LVEF  $\leq 30\%$ . Patients were randomized 3:2 to CRT with ICD or ICD alone and followed up for a mean of 2.4 years. The end-point of the study was the reduction in all-cause mortality and/or hospitalizations for HF. CRT with ICD showed a significant advantage over ICD alone with regard to the primary end-point (17.2% vs 25.3%, HR 0.66, 95% CI 0.52-0.84,  $P = 0.001$ ), the reduction in left ventricular volume (LVEsV -57 mL vs -18 mL, LVEdV -52 mL vs -15 mL,  $P < 0.01$ , CRT with ICD vs ICD alone, respectively) and the increase in LVEF (+11% vs +3%,  $P < 0.001$ , CRT with ICD vs ICD alone). The MADIT-CRT results were largely confirmed by the RAFT study<sup>[31]</sup>, which enrolled 1798 HF patients in NYHA class II (80%) and III, with QRS  $\geq 130$  ms, LVEF  $\leq 30\%$ , randomized to CRT with ICD or ICD alone and followed up for 40 months. The reduction in the primary end-point of all-cause mortality/hospitalizations for HF was 25% greater in the CRT with ICD group than in the ICD alone group (HR 0.75, 95% CI 0.64-0.87,  $P < 0.001$ ), with 29% reduction of the risk of mortality in the sub-group of patients in NYHA class II. The results of these three studies (REVERSE, MADIT-CRT and RAFT) encouraged CRT indications to be extended to all NYHA class II patients. Moreover, a recent meta-analysis of 5 randomized studies has shown that CRT provides greater benefits in patients with QRS  $>150$  ms<sup>[32]</sup>.

## GUIDELINES

On the basis of the evidences collected, the main American and European scientific societies have modified CRT indications in the aim to include patients not only in NYHA classes III and IV, but also in NYHA class II with LBBB, in particular if with QRS  $>150$  ms<sup>[33,34]</sup>. The benefit of CRT in patients in sinus rhythm with wide QRS but without LBBB is uncertain. In these patients, the indication for CRT is therefore less prescriptive.

Furthermore, in HF patients in permanent atrial fibrillation with wide QRS and left ventricular dysfunction, CRT is indicated only in an advanced NYHA class and on condition that 100% biventricular stimulation can be achieved, even through AV junction ablation if needed. Finally, there is indication to up-grade a conventional PMK or ICD to CRT or CRT with ICD in HF patients in an advanced NYHA class with left ventricular dysfunction and a high percentage of ventricular pacing.

As yet, in patients with mild-moderate left ventricular dysfunction in whom conventional pacing is indicated, the indication for “de novo” CRT implantation, in order to reduce the risk of HF worsening

due to the high percentage of right apical pacing, is less established.

## LIMITS

Because of its widespread involvement of clinical, instrumental, metabolic and endocrine factors, the response to CRT is not easy to precisely establish. Nevertheless, there is general agreement that patients in whom the LVEDV reduction in the medium/long term is less than 15% should be classed as non-responders. This is not a low percentage, mostly considering that these patients account for at least 30% of all undergoing implantations<sup>[35]</sup>. The response to CRT may be sub-optimal for many reasons, ranging from the etiopathogenic and clinical heterogeneity of HF patients to the widespread and variable presence of co-morbidities or to the lack of optimization of medical therapy<sup>[36]</sup>.

In the aim to increase the probability of response to CRT, it is important to ensure that left ventricular stimulation is concordant with the most delayed activation site, as identified by Tissue Doppler Imaging<sup>[37]</sup> or speckle-tracking<sup>[38]</sup> echocardiography. Moreover, the presence of large areas of fibrous scarring in the left ventricle can impair the CRT response<sup>[39]</sup>, particularly if these are located in the posterior-lateral wall<sup>[40]</sup>. By contrast, the presence of vital myocardium, as identified by means of echo-dobutamine<sup>[41]</sup> or nuclear medicine techniques<sup>[42,43]</sup>, has a favorable prognostic significance in CRT candidates. Briefly, in order to reduce the percentage of non-responders to CRT, it is necessary to optimize the prognostic stratification of candidates for implantation through multi-parameter evaluations<sup>[44]</sup> and to ensure correct device programming, with periodic updates of the A-V and V-V intervals which are widely recommended but not so often performed<sup>[45]</sup>.

At last, the recent diffusion of remote control systems for implanted devices has improved the assistance available to CRT patients through strict monitoring of numerous vital parameters during follow-up<sup>[46]</sup>. Indeed, a strong association between remote monitoring and survival has been observed in CRT-ICD patients<sup>[47]</sup>.

## PERSPECTIVES

### Lead positioning

Alternative forms of CRT, including biventricular endocardial and multisite epicardial pacing, have been recently proposed. Left ventricular leads cannot be implanted in up to 10% of patients undergoing CRT implantation<sup>[48]</sup>. These implant failures are not due to patient selection but rather challenges posed by anatomy leading to lead stability problems, phrenic nerve stimulation, and poor electrical measurements<sup>[49]</sup>. The quadripolar leads recently made available in the market, allowing multiple pacing configurations, provide an opportunity to optimize the electrical performance and minimize phrenic nerve stimulation. Moreover, preliminary data suggest that simultaneous stimulation of multiple left ventricular sites using two or more pacing sites in a quadripolar lead could enhance the acute effectiveness of CRT<sup>[50]</sup>. However, the results appear conflicting<sup>[51,52]</sup> and prospective follow-up studies are required to demonstrate clinical benefit.

During CRT device implantation, the pacing lead is usually positioned in the coronary sinus to stimulate the left ventricular epicardium. Transvenous left ventricular endocardial pacing via transeptal puncture has been proposed as an alternative method. Several experimental studies have demonstrated that endocardial pacing should elicit beneficial effects, allowing more homogeneous and rapid electric depolarization and repolarization<sup>[53,54]</sup>. In particular, pacing at an optimal individual endocardial site seems

to yield enhanced left ventricular performance in comparison with conventional coronary sinus site stimulation<sup>[55]</sup>. Thus, endocardial left ventricular pacing might provide an alternative approach to CRT, when coronary sinus pacing is not viable. However, the possibility of adverse effects of endocardial CRT (eg, the risk of thromboembolic complications and the induction of mitral valve dysfunction) should be considered and carefully addressed during the evaluation of risks and benefits of the procedure.

### Patient selection

As previously reported, duration of QRS interval  $\geq 120$  or 130 ms was the inclusion criterion used in major CRT trials. However, sub-group analyses based on QRS morphology<sup>[30,31,56]</sup> and a meta-analysis<sup>[57]</sup> suggested that patients with complete LBBB showed a greater benefit on the composite of morbidity/mortality from CRT, compared with patients with non-specific intraventricular conduction delay or right bundle branch block. Based on this evidence, current class I recommendations were restricted to patients with complete LBBB. However, recent studies showed that fragmented QRS complexes in the electrocardiograms of patients with nonischemic dilated cardiomyopathy and narrow QRS complexes are associated with significant intraventricular dyssynchrony<sup>[58,59]</sup>, and other studies suggested that fragmented QRS complexes might be useful in predicting response to CRT<sup>[60,61]</sup>. Ongoing studies are investigating the possibility of maximizing CRT benefits by refining ECG selection criteria<sup>[62]</sup>.

Several studies have addressed the issue of the interventricular and left intraventricular dyssynchrony caused by right apical pacing. These studies have tested “de novo” CRT implantation in patients with a conventional pacing indication, both with preserved left ventricular systolic function<sup>[63-65]</sup> and with moderate-severe left ventricular dysfunction<sup>[66-68]</sup>. The results suggest that CRT plays a preventive role with regard to HF mortality/hospitalizations only in patients with left ventricular dysfunction (LVEF <40%). Indeed, left ventricular systolic dysfunction has recently been suggested as an independent predictor of the adverse clinical impact of pacing<sup>[69,70]</sup>, even though the preventive impact of CRT on HF in these patients must be carefully evaluated considering the increase in complications due to the greater number of leads implanted (6.5% vs 18%, conventional pacing vs CRT in the BLOCK-HF study)<sup>[68]</sup>.

An alternative strategy in these patients is to up-grade to CRT after first implanting a conventional PMK. This approach provides the same clinical benefit as “de novo” CRT implantation, but is however associated with a considerable percentage of complications<sup>[71]</sup>.

Further evidence of the potential benefit of “de novo” CRT implantation in patients with conventional pacing indications in whom right apical stimulation cannot be avoided is expected from the BIOPACE trial (ClinicalTrials.gov Identifier: NCT00187278), while the on-going MIRACLE-EF study (ClinicalTrials.gov Identifier: NCT01735916) is testing the efficacy of CRT in patients with left ventricular dysfunction (LVEF 36%-50%) and LBBB but without indication for definitive pacing.

Finally, in patients with a prolonged PR interval, LBBB and left ventricular dysfunction, the REAL-CRT (BiventRicular pacing in prolongEd AV interval) study will evaluate the synergic effect of atrio-ventricular and inter-ventricular synchronization provided by CRT in patients with a minimum or intermittent indication for pacing (ClinicalTrials.gov Identifier: NCT02150538).

## CONCLUSIONS

A large number of studies have already demonstrated that, compared

with optimal medical therapy alone, CRT can reduce HF mortality and hospitalizations in selected HF patients in NYHA classes II-IV. Whether indications for CRT should be extended to patients with an indication for convention pacing, mild-moderate (or even no) left ventricular dysfunction and a high percentage of right apical pacing will need to be evaluated in view of the expected increase in complications due to the greater number of leads implanted.

## CONFLICT OF INTERESTS

Sergio Valsecchi, Umberto Riva are employees of Boston Scientific Italy; There are no other conflicts of interest with regard to the present study.

## REFERENCES

- Nieminen MS, Harjola VP. Definition and epidemiology of acute heart failure syndromes. *Am J Cardiol* 2005; **96**: 5G-10G
- Massie BM, Packer M. Congestive heart failure: current controversies and future prospects. *Am J Cardiol* 1990; **66**: 429-430
- Heidenreich PA, Albert NM, Allen LA, Bluemke DA, Butler J, Fonarow GC, Ikonomicis JS, Khavjou O, Konstam MA, Maddox TM, Nichol G, Pham M, Piña IL, Trogon JG; American Heart Association Advocacy Coordinating Committee; Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Cardiovascular Radiology and Intervention; Council on Clinical Cardiology; Council on Epidemiology and Prevention; Stroke Council. Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association. *Circ Heart Fail* 2013; **6**: 606-619
- Anter E, Jessup M, Callans DJ. Atrial fibrillation and heart failure: treatment considerations for a dual epidemic. *Circulation* 2009; **119**: 2516-2525
- Jessup M, Brozena S. Heart failure. *N Engl J Med* 2003; **348**: 2007-2018
- Metra M, Ponikowski P, Dickstein K, McMurray JJ, Gavazzi A, Bergh CH, Fraser AG, Jaarsma T, Pitsis A, Mohacsi P, Böhm M, Anker S, Dargie H, Brutsaert D, Komajda M; Heart Failure Association of the European Society of Cardiology. Advanced chronic heart failure: A position statement from the Study Group on Advanced Heart Failure of the Heart Failure Association of the European Society of Cardiology. *Eur J Heart Fail* 2007; **9**: 684-694
- Gottipaty VK, Krelis SP, Lu F, Spencer EP, Shusterman V, Weiss R, Brode S, White A, Anderson KP, White BG, Feldman AM For the VEST investigators; University of Pittsburgh, Pittsburgh PA, USA. The Resting Electrocardiogram Provides a Sensitive and Inexpensive Marker of Prognosis in Patients with Chronic Congestive Heart Failure. *J Am Coll Cardiol* 1999; **33**:145A [Abstr. 847-4]
- Blanc JJ, Etienne Y, Gilard M, Mansourati J, Munier S, Boschat J, Benditt DG, Lurie KG. Evaluation of different ventricular pacing sites in patients with severe heart failure: results of an acute hemodynamic study. *Circulation* 1997; **96**: 3273-3277
- Kass DA, Chen CH, Curry C, Talbot M, Berger R, Fetis B, Nevo E. Improved left ventricular mechanics from acute VDD pacing in patients with dilated cardiomyopathy and ventricular conduction delay. *Circulation* 1999; **99**: 1567-1573
- Russell K, Smiseth OA, Gjesdal O, Qvigstad E, Norseng PA, Sjaastad I, Opdahl A, Skulstad H, Edvardsen T, Remme EW. Mechanism of prolonged electromechanical delay in late activated myocardium during left bundle branch block. *Am J Physiol Heart Circ Physiol* 2011; **301**: H2334-H2343
- Lund LH, Jurga J, Edner M, Benson L, Dahlström U, Linde C, Alehagen U. Prevalence, correlates, and prognostic significance of QRS prolongation in heart failure with reduced and preserved ejection fraction. *Eur Heart J* 2013; **34**: 529-539
- Clark AL, Goode K, Cleland JG. The prevalence and incidence of left bundle branch block in ambulant patients with chronic heart failure. *Eur J Heart Fail* 2008; **10**: 696-702
- Kyriacou A, Pabari PA, Mayet J, Peters NS, Davies DW, Lim PB, Lefroy D, Hughes AD, Kanagaratnam P, Francis DP, Whinnett ZI. Cardiac resynchronization therapy and AV optimization increase myocardial oxygen consumption, but increase cardiac function more than proportionally. *Int J Cardiol* 2014; **171**: 144-152
- Freeman JV, Masoudi FA. Effectiveness of implantable cardioverter defibrillators and cardiac resynchronization therapy in heart failure. *Heart Fail Clin* 2013; **9**: 59-77
- Gras D, Leclercq C, Tang AS, Bucknall C, Luttikhuis HO, Kirstein-Pedersen A. Cardiac resynchronization therapy in advanced heart failure the multicenter InSync clinical study. *Eur J Heart Fail* 2002; **4**: 311-320
- Kühlkamp V; InSync 7272 ICD World Wide Investigators. Initial experience with an implantable cardioverter-defibrillator incorporating cardiac resynchronization therapy. *J Am Coll Cardiol* 2002; **39**: 790-797
- Abraham WT, Fisher WG, Smith AL, Delurgio DB, Leon AR, Loh E, Kocovic DZ, Packer M, Clavell AL, Hayes DL, Ellestad M, Trupp RJ, Underwood J, Pickering F, Truex C, McAtee P, Messenger J; MIRACLE Study Group. Multicenter InSync Randomized Clinical Evaluation. Cardiac resynchronization in chronic heart failure. *N Engl J Med* 2002; **346**: 1845-1853
- Young JB, Abraham WT, Smith AL, Leon AR, Lieberman R, Wilkoff B, Canby RC, Schroeder JS, Liem LB, Hall S, Wheelan K; Multicenter InSync ICD Randomized Clinical Evaluation (MIRACLE ICD) Trial Investigators. Combined cardiac resynchronization and implantable cardioversion defibrillation in advanced chronic heart failure: the MIRACLE ICD Trial. *JAMA* 2003; **289**: 2685-2694
- Cazeau S, Leclercq C, Lavergne T, Walker S, Varma C, Linde C, Garrigue S, Kappenberger L, Haywood GA, Santini M, Bailleul C, Daubert JC; Multisite Stimulation in Cardiomyopathies (MUSTIC) Study Investigators. Effects of multisite biventricular pacing in patients with heart failure and intraventricular conduction delay. *N Engl J Med* 2001; **344**: 873-880
- Auricchio A, Stellbrink C, Sack S, Block M, Vogt J, Bakker P, Huth C, Schöndube F, Wolfhard U, Böcker D, Krahnfeld O, Kirkels H; Pacing Therapies in Congestive Heart Failure (PATHCHF) Study Group. Long-term clinical effect of hemodynamically optimized cardiac resynchronization therapy in patients with heart failure and ventricular conduction delay. *J Am Coll Cardiol* 2002; **39**: 2026-2033
- Auricchio A, Stellbrink C, Butter C, Sack S, Vogt J, Misier AR, Böcker D, Block M, Kirkels JH, Kramer A, Huvelle E; Pacing Therapies in Congestive Heart Failure II Study Group; Guidant Heart Failure Research Group. Clinical efficacy of cardiac resynchronization therapy using left ventricular pacing in heart failure patients stratified by severity of ventricular conduction delay. *J Am Coll Cardiol* 2003; **42**: 2109-2116
- Bristow MR, Saxon LA, Boehmer J, Krueger S, Kass DA, De Marco T, Carson P, DiCarlo L, DeMets D, White BG, DeVries DW, Feldman AM; Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) Investigators. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. *N Engl J Med* 2004; **350**: 2140-2150
- Cleland JG, Daubert JC, Erdmann E, Freemantle N, Gras D, Kappenberger L, Tavazzi L; Cardiac Resynchronization-Heart Failure (CARE-HF) Study Investigators. The effect of cardiac resynchronization on morbidity and mortality in heart failure. *N Engl J Med* 2005; **352**: 1539-1549
- The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomized trial. *Lancet* 1999; **353**: 9-13

- 25 Packer M, Fowler MB, Roecker EB, Coats AJ, Katus HA, Krum H, Mohacsi P, Rouleau JL, Tendera M, Staiger C, Holcslaw TL, Amann-Zalan I, DeMets DL; Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study Group. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. *Circulation* 2002; **106**: 2194-2199
- 26 Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The SOLVD Investigators. *N Engl J Med* 1992; **327**: 685-691
- 27 Kjekshus J, Swedberg K, Snapinn S. Effects of enalapril on long-term mortality in severe congestive heart failure. CONSENSUS Trial Group. *Am J Cardiol* 1992; **69**: 103-107
- 28 Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (the Randomized Aldactone Evaluation Study [RALES]). *Am J Cardiol* 1996; **78**: 902-907
- 29 Linde C, Abraham WT, Gold MR, St John Sutton M, Ghio S, Daubert C; REVERSE (REsynchronization reVERses Remodeling in Systolic left vEntricular dysfunction) Study Group. Randomized trial of cardiac resynchronization in mildly symptomatic heart failure patients and in asymptomatic patients with left ventricular dysfunction and previous heart failure symptoms. *J Am Coll Cardiol* 2008; **52**: 1834-1843
- 30 Moss AJ, Hall WJ, Cannom DS, Klein H, Brown MW, Daubert JP, Estes NA 3rd, Foster E, Greenberg H, Higgins SL, Pfeiffer MA, Solomon SD, Wilber D, Zareba W; MADIT-CRT Trial Investigators. Cardiac-resynchronization therapy for the prevention of heart-failure events. *N Engl J Med* 2009; **361**: 1329-1338
- 31 Tang AS, Wells GA, Talajic M, Arnold MO, Sheldon R, Connolly S, Hohnloser SH, Nichol G, Birnie DH, Sapp JL, Yee R, Healey JS, Rouleau JL; Resynchronization-Defibrillation for Ambulatory Heart Failure Trial Investigators. Cardiac-resynchronization therapy for mild-to-moderate heart failure. *N Engl J Med* 2010; **363**: 2385-1395
- 32 Cleland JG, Abraham WT, Linde C, Gold MR, Young JB, Claude Daubert J, Sherfese L, Wells GA, Tang AS. An individual patient meta-analysis of five randomized trials assessing the effects of cardiac resynchronization therapy on morbidity and mortality in patients with symptomatic heart failure. *Eur Heart J* 2013; **34**: 3547-3556
- 33 Tracy CM, Epstein AE, Darbar D, Dimarco JP, Dunbar SB, Estes NA 3rd, Ferguson TB Jr, Hammill SC, Karasik PE, Link MS, Marine JE, Schoenfeld MH, Shanker AJ, Silka MJ, Stevenson LW, Stevenson WG, Varosy PD. 2012 ACCF/AHA/HRS focused update of the 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. *J Am Coll Cardiol* 2012; **60**: 1297-1313
- 34 Brignole M, Auricchio A, Baron-Esquivias G, Bordachar P, Boriani G, Breithardt OA, Cleland J, Deharo JC, Delgado V, Elliott PM, Gorenek B, Israel CW, Leclercq C, Linde C, Mont L, Padeletti L, Sutton R, Vardas PE; ESC Committee for Practice Guidelines (CPG), Zamorano JL, Achenbach S, Baumgartner H, Bax JJ, Bueno H, Dean V, Deaton C, Erol C, Fagard R, Ferrari R, Hasdai D, Hoes AW, Kirchhof P, Knuuti J, Kolh P, Lancellotti P, Linhart A, Nihoyannopoulos P, Piepoli MF, Ponikowski P, Sirnes PA, Tamaro JL, Tendera M, Torbicki A, Wijns W, Windecker S; Document Reviewers, Kirchhof P, Blomstrom-Lundqvist C, Badano LP, Aliyev F, Bänsch D, Baumgartner H, Bsata W, Buser P, Charron P, Daubert JC, Dobeanu D, Faerstrand S, Hasdai D, Hoes AW, Le Heuzey JY, Mavrakis H, McDonagh T, Merino JL, Nawar MM, Nielsen JC, Pieske B, Poposka L, Ruschitzka F, Tendera M, Van Gelder IC, Wilson CM. 2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy: the Task Force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association (EHRA). *Eur Heart J* 2013; **34**: 2281-2329
- 35 Birnie DH, Tang AS. The problem of non-response to cardiac resynchronization therapy. *Curr Opin Cardiol* 2006; **21**: 20-26
- 36 Mullens W, Grimm RA, Verga T, Dresing T, Starling RC, Wilkoff BL, Tang WH. Insights from a cardiac resynchronization optimization clinic as part of a heart failure disease management program. *J Am Coll Cardiol* 2009; **53**: 765-773
- 37 Ansalone G, Giannantoni P, Ricci R, Trambaiolo P, Fedele F, Santini M. Doppler myocardial imaging to evaluate the effectiveness of pacing sites in patients receiving biventricular pacing. *J Am Coll Cardiol* 2002; **39**: 489-499
- 38 Ypenburg C, van Bommel RJ, Delgado V, Mollema SA, Bleeker GB, Boersma E, Schalij MJ, Bax JJ. Optimal left ventricular lead position predicts reverse remodeling and survival after cardiac resynchronization therapy. *J Am Coll Cardiol* 2008; **52**: 1402-1409
- 39 Ypenburg C, Roes SD, Bleeker GB, Kaandorp TA, de Roos A, Schalij MJ, van der Wall EE, Bax JJ. Effect of total scar burden on contrast-enhanced magnetic resonance imaging on response to cardiac resynchronization therapy. *Am J Cardiol* 2007; **99**: 657-660
- 40 Bleeker GB, Kaandorp TA, Lamb HJ, Boersma E, Steendijk P, de Roos A, van der Wall EE, Schalij MJ, Bax JJ. Effect of posterolateral scar tissue on clinical and echocardiographic improvement after cardiac resynchronization therapy. *Circulation* 2006; **113**: 969-976
- 41 Ypenburg C, Sieders A, Bleeker GB, Holman ER, van der Wall EE, Schalij MJ, Bax JJ. Myocardial contractile reserve predicts improvement in left ventricular function after cardiac resynchronization therapy. *Am Heart J* 2007; **154**: 1160-1165
- 42 Ypenburg C, Schalij MJ, Bleeker GB, Steendijk P, Boersma E, Dibbets-Schneider P, Stokkel MP, van der Wall EE, Bax JJ. Extent of viability to predict response to cardiac resynchronization therapy in ischemic heart failure patients. *J Nucl Med* 2006; **47**: 1565-1570
- 43 Ypenburg C, Schalij MJ, Bleeker GB, Steendijk P, Boersma E, Dibbets-Schneider P, Stokkel MP, van der Wall EE, Bax JJ. Impact of viability and scar tissue on response to cardiac resynchronization therapy in ischaemic heart failure patients. *Eur Heart J* 2007; **28**: 33-41
- 44 Auricchio A, Prinzen FW. Non-responders to cardiac resynchronization therapy: the magnitude of the problem and the issues. *Circ J* 2011; **75**: 521-527
- 45 Burri H, Sunthorn H, Shah D, Lerch R. Optimization of device programming for cardiac resynchronization therapy. *Pacing Clin Electrophysiol* 2006; **29**: 1416-1425
- 46 Lazarus A. Remote, wireless, ambulatory monitoring of implantable pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy systems: analysis of a worldwide database. *Pacing Clin Electrophysiol* 2007; **30 Suppl 1**: S2-S12
- 47 Saxon LA, Hayes DL, Gilliam FR, Heidenreich PA, Day J, Seth M, Meyer TE, Jones PW, Boehmer JP. Long-term outcome after ICD and CRT implantation and influence of remote device follow-up: the ALTITUDE survival study. *Circulation* 2010; **122**: 2359-2367
- 48 Dickstein K, Bogale N, Priori S, Auricchio A, Cleland JG, Gitt A, Limbourg T, Linde C, van Veldhuisen DJ, Brugada J; Scientific Committee; National Coordinators. The European cardiac resynchronization therapy survey. *Eur Heart J* 2009; **30**: 2450-2460
- 49 Biffi M, Moschini C, Bertini M, Saporito D, Ziacchi M, Diemberger I, Valzania C, Domenichini G, Cervi E, Martignani C, Sangiorgi D, Branzi A, Boriani G. Phrenic stimulation: a challenge for cardiac resynchronization therapy. *Circ Arrhythm Electrophysiol* 2009; **2**: 402-410
- 50 Pappone C, Čalović Ž, Vicedomini G, Cuko A, McSpadden LC, Ryu K, Romano E, Saviano M, Baldi M, Pappone A, Ciac-

- cio C, Giannelli L, Ionescu B, Petretta A, Vitale R, Fundaliotis A, Tavazzi L, Santinelli V. Multipoint left ventricular pacing improves acute hemodynamic response assessed with pressure-volume loops in cardiac resynchronization therapy patients. *Heart Rhythm* 2014; **11**: 394-401
- 51 Padeletti L, Colella A, Michelucci A, Pieragnoli P, Ricciardi G, Porciani MC, Tronconi F, Hettrick DA, Valsecchi S. Dual-site left ventricular cardiac resynchronization therapy. *Am J Cardiol* 2008; **102**: 1687-1692
- 52 Shetty AK, Sohal M, Chen Z, Ginks MR, Bostock J, Amraoui S, Ryu K, Rosenberg SP, Niederer SA, Gill J, Carr-White G, Razavi R, Rinaldi CA. A comparison of left ventricular endocardial, multi-site, and multipolar epicardial cardiac resynchronization: an acute haemodynamic and electroanatomical study. *Europace* 2014; **16**: 873-879
- 53 van Deursen C, van Geldorp IE, Rademakers LM, van Hunnik A, Kuiper M, Klersy C, Auricchio A, Prinzen FW. Left ventricular endocardial pacing improves resynchronization therapy in canine left bundle-branch hearts. *Circ Arrhythm Electrophysiol* 2009; **2**: 580-587
- 54 Ginks MR, Lambiase PD, Duckett SG, Bostock J, Chinchapatnam P, Rhode K, McPhail MJ, Simon M, Bucknall C, Carr-White G, Razavi R, Rinaldi CA. A simultaneous X-Ray/MRI and non-contact mapping study of the acute hemodynamic effect of left ventricular endocardial and epicardial cardiac resynchronization therapy in humans. *Circ Heart Fail* 2011; **4**: 170-179
- 55 Padeletti L, Pieragnoli P, Ricciardi G, Perrotta L, Grifoni G, Porciani MC, Lionetti V, Valsecchi S. Acute hemodynamic effect of left ventricular endocardial pacing in cardiac resynchronization therapy: assessment by pressure-volume loops. *Circ Arrhythm Electrophysiol* 2012; **5**: 460-467
- 56 Zareba W, Klein H, Cygankiewicz I, Hall WJ, McNitt S, Brown M, Cannon D, Daubert JP, Eldar M, Gold MR, Goldberger JJ, Goldenberg I, Lichstein E, Pitschner H, Rashtian M, Solomon S, Viskin S, Wang P, Moss AJ; MADIT-CRT Investigators. Effectiveness of Cardiac Resynchronization Therapy by QRS Morphology in the Multicenter Automatic Defibrillator Implantation Trial-Cardiac Resynchronization Therapy (MADIT-CRT). *Circulation* 2011; **123**: 1061-1072
- 57 Sipahi I, Carrigan TP, Rowland DY, Stambler BS, Fang JC. Impact of QRS duration on clinical event reduction with cardiac resynchronization therapy: meta-analysis of randomized controlled trials. *Arch Intern Med* 2011; **171**: 1454-1462
- 58 Yusuf J, Agrawal DK, Mukhopadhyay S, Mehta V, Trehan V, Tyagi S. Fragmented narrow QRS complex: predictor of left ventricular dyssynchrony in non-ischemic dilated cardiomyopathy. *Indian Heart J* 2013; **65**: 172-179
- 59 Tigen K, Karaahmet T, Gurel E, Cevik C, Nugent K, Pala S, Tanalp AC, Mutlu B, Basaran Y. The utility of fragmented QRS complexes to predict significant intraventricular dyssynchrony in nonischemic dilated cardiomyopathy patients with a narrow QRS interval. *Can J Cardiol* 2009; **25**: 517-522
- 60 Celikyurt U, Agacdiken A, Sahin T, Al N, Vural A, Ural D. Relationship between fragmented QRS and response to cardiac resynchronization therapy. *J Interv Card Electrophysiol* 2012; **35**: 337-342
- 61 Celikyurt U, Agacdiken A, Sahin T, Al N, Kozdag G, Vural A, Ural D. Number of leads with fragmented QRS predicts response to cardiac resynchronization therapy. *Clin Cardiol* 2013; **36**: 36-39
- 62 Stabile G, Bertaglia E, Botto G, Isola F, Mascioli G, Pepi P, Caico SI, De Simone A, D'Onofrio A, Pecora D, Palmisano P, Maglia G, Arena G, Malacrida M, Padeletti L. Cardiac Resynchronization Therapy MODular REgistry: ECG and Rx predictors of response to cardiac resynchronization therapy (NCT01573091). *J Cardiovasc Med (Hagerstown)* 2013; **14**: 886-893
- 63 Albertsen AE, Nielsen JC, Poulsen SH, Mortensen PT, Pedersen AK, Hansen PS, Jensen HK, Egeblad H. Biventricular pacing preserves left ventricular performance in patients with high-grade atrio-ventricular block: a randomized comparison with DDD(R) pacing in 50 consecutive patients. *Europace* 2008; **10**: 314-320
- 64 Chan JY, Fang F, Zhang Q, Fung JW, Razali O, Azlan H, Lam KH, Chan HC, Yu CM. Biventricular pacing is superior to right ventricular pacing in bradycardia patients with preserved systolic function: 2-year results of the PACE trial. *Eur Heart J* 2011; **32**: 2533-2540
- 65 Stockburger M, Gómez-Doblas JJ, Lamas G, Alzueta J, Fernández-Lozano I, Cobo E, Wiegand U, Concha JF, Navarro X, Navarro-López F, de Teresa E. Preventing ventricular dysfunction in pacemaker patients without advanced heart failure: results from a multicentre international randomized trial (PREVENT-HF). *Eur J Heart Fail* 2011; **13**: 633-641
- 66 Kindermann M, Hennen B, Jung J, Geisel J, Böhm M, Fröhlig G. Biventricular versus conventional right ventricular stimulation for patients with standard pacing indication and left ventricular dysfunction: the Homburg Biventricular Pacing Evaluation (HO-BIPACE). *J Am Coll Cardiol* 2006; **47**: 1927-1937
- 67 Martinelli Filho M, de Siqueira SF, Costa R, Greco OT, Moreira LF, D'Avila A, Heist EK. Conventional versus biventricular pacing in heart failure and bradyarrhythmia: the COMBAT study. *J Card Fail* 2010; **16**: 293-300
- 68 Curtis AB, Worley SJ, Adamson PB, Chung ES, Niazi I, Sherfese L, Shinn T, Sutton MS; Biventricular versus Right Ventricular Pacing in Heart Failure Patients with Atrioventricular Block (BLOCK HF) Trial Investigators. Biventricular pacing for atrioventricular block and systolic dysfunction. *N Engl J Med* 2013; **368**: 1585-1593
- 69 Mazza A, Bendini MG, Leggio M, Riva U, Ciardiello C, Valsecchi S, De Cristofaro R, Giordano G. Incidence and predictors of heart failure hospitalization and death in permanent pacemaker patients: a single-centre experience over medium-term follow-up. *Europace* 2013; **15**: 1267-1272
- 70 De Sisti A, Márquez MF, Tonet J, Bonny A, Frank R, Hidden-Lucet F. Adverse effects of long-term right ventricular apical pacing and identification of patients at risk of atrial fibrillation and heart failure. *Pacing Clin Electrophysiol* 2012; **35**: 1035-1043
- 71 Poole JE, Gleva MJ, Mela T, Chung MK, Uslan DZ, Borge R, Gottipaty V, Shinn T, Dan D, Feldman LA, Seide H, Winston SA, Gallagher JJ, Langberg JJ, Mitchell K, Holcomb R; REPLACE Registry Investigators. Complication rates associated with pacemaker or implantable cardioverter-defibrillator generator replacements and upgrade procedures: results from the REPLACE registry. *Circulation*. 2010; **122**: 1553-1561

**Peer reviewer:** Yengi Umut Celikyurt, MD, Department of Cardiology, Kocaeli University, Umuttepe Yerleskesi, Kocaeli, 41380, Turkey.